KEMCO

AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment

AbbVie Inc. (NYSE:ABBV) is one of the best dividend aristocrat stocks to buy now. On June 19, AbbVie Inc. (NYSE:ABBV) delivered topline Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress. The results from the Phase 3 CLL14 trial affirm venetoclax’s enduring safety and efficacy in untreated chronic […]

Blakeman slams Lander in TV interview over Israel stance

Eastman Expands Portfolio With Jarylec Dielectric Fluids Buyout

EMN expands in dielectric fluids with Jarylec acquisition, adding assets from Arkema and strengthening its power grid applications portfolio.

Trump-endorsed Collins beats Kemp’s pick to take on Ossoff for Georgia Senate

Eli Lilly (LLY) Buys 4E Therapeutics As Jaypirca Hits Key Leukemia Milestone

Eli Lilly (NYSE:LLY) is acquiring 4E Therapeutics, adding MNK inhibitor candidates aimed at non opioid chronic pain treatment. The deal expands Lilly's neuroscience pipeline beyond its existing focus on metabolic and diabetes therapies. Jaypirca has reached a key clinical milestone in the Phase 3 BRUIN CLL-322 trial in relapsed or refractory chronic lymphocytic leukemia when used with venetoclax and rituximab. These developments represent fresh, material updates for Eli Lilly that relate...

Got $10,000? Starbucks vs. McDonald’s: The Winner for Long-Term Investors

Starbucks (NASDAQ: SBUX) and McDonald’s (NYSE: MCD) both delivered upbeat quarters this spring, but the stories underneath could not be more different. Starbucks is mid-turnaround under CEO Brian Niccol, while McDonald’s is a steady franchised cash machine led by Chris Kempczinski. If you are deciding where to park $10,000, the choice comes down to turnaround ... Got $10,000? Starbucks vs. McDonald’s: The Winner for Long-Term Investors

Georgia showdown pits Trump vs Kemp in GOP Senate race

We’re about to find out how powerful Brian Kemp really is with Georgia Republicans

Georgia GOP runoff sets up Senate and governor fights with Trump and Kemp on opposite sides

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The study met its primary endpoint of independent review committee (IRC)-assessed progression-free survival (PFS), demonstrating that the ad